Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac function evolution during PD-1 inhibitor immunotherapy (nivolumab)
2017-001197-42Phase 4Active
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Left ventricular global longitudinal strain evolution. Started Jun 2017; status: active.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2017-001197-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001197-42.